The Mays Cancer Center at UT Health San Antonio and Evestra Inc., a San Antonio-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from NIH for the research and development of a drug targeting ovarian cancer, EC359. It is the first grant of this kind awarded to The University of Texas Health Science Center at San Antonio.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe